Japó - anglès - すりの適正使用協議会 RAD-AR Council, Japan

astrazeneca k.k - terbutaline sulfate - tablet (φapprox. 7.0mm, thickness approx. 2.7mm)

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - metformin hydrochloride, quantity: 500 mg - tablet, modified release - excipient ingredients: colloidal anhydrous silica; magnesium stearate; povidone; hypromellose - treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin modified release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - metformin hydrochloride, quantity: 1000 mg - tablet, modified release - excipient ingredients: hypromellose; povidone; magnesium stearate; colloidal anhydrous silica - treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin modified release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - metformin hydrochloride, quantity: 500 mg - tablet, modified release - excipient ingredients: carmellose sodium; copovidone; magnesium stearate; hypromellose; microcrystalline cellulose - metformin is indicated in the treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin hcl extended release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - metformin hydrochloride, quantity: 750 mg - tablet, modified release - excipient ingredients: carmellose sodium; magnesium stearate; copovidone; hypromellose; microcrystalline cellulose - metformin is indicated in the treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin hcl extended release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - metformin hydrochloride, quantity: 500 mg - tablet, modified release - excipient ingredients: microcrystalline cellulose; magnesium stearate; carmellose sodium; copovidone; hypromellose - metformin is indicated in the treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin hcl extended release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - metformin hydrochloride, quantity: 750 mg - tablet, modified release - excipient ingredients: magnesium stearate; microcrystalline cellulose; hypromellose; carmellose sodium; copovidone - metformin is indicated in the treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin hcl extended release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - metformin hydrochloride, quantity: 500 mg - tablet, modified release - excipient ingredients: carmellose sodium; hypromellose; microcrystalline cellulose; copovidone; magnesium stearate - metformin is indicated in the treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin hcl extended release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - metformin hydrochloride, quantity: 750 mg - tablet, modified release - excipient ingredients: carmellose sodium; magnesium stearate; microcrystalline cellulose; copovidone; hypromellose - metformin is indicated in the treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin hcl extended release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - metformin hydrochloride, quantity: 1000 mg - tablet, modified release - excipient ingredients: microcrystalline cellulose; povidone; hypromellose; carmellose sodium; copovidone; magnesium stearate - metformin is indicated in the treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin hcl extended release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin